CD274 and neoplasm: In mouse models, PD-L1–/– hosts have been reported to show improved antitumor immunity in some model systems39,40, but in other models CRISPR/Cas9-mediated disruption of the PD-L1 gene in tumor cells can be sufficient for improved tumor control41.